Xingruida XDR
Finnrick has tested 71 samples from Xingruida XDR across 6 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| Melanotan II | 2 | 18 Jul 2025 | 31 Jul 2025 | |||||
| BPC-157 | 8 | 24 Jul 2025 | 27 May 2026 | |||||
| GHK-Cu | 9 | 25 Nov 2025 | 13 May 2026 | |||||
| Tesamorelin | 7 | 17 Jul 2025 | 27 May 2026 | |||||
| Retatrutide | 25 | 20 Jun 2025 | 25 May 2026 | |||||
| Tirzepatide | 20 | 4 Sep 2025 | 15 May 2026 | |||||
The Xingruida XDR samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 13 overall satisfaction reports
People who submitted test requests to Finnrick gave Xingruida XDR an average satisfaction rating of 3.9 out of 5 across 13 reports associated with samples received and tested by Finnrick. Customers rated packaging quality (4.7/5) particularly highly.
Most recent Xingruida XDR tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 27 May 2026 | Tesamorelin | View | 10mg | 10.8mg | +8.0% | 99.80% | Mar 2, 2026 | No label / Silver crimp / Black cap | Lab E | Public | |
| 27 May 2026 | BPC-157 | View | 5mg | 4.48mg | -10.4% | 99.00% | Mar. 2, 2026 | No label / Silver crimp / Red cap | Lab E | Public | |
| 25 May 2026 | Retatrutide | View | 30mg | 31.9mg | +6.3% | 99.50% | Mar.2,2026 | No label / Silver crimp / Blue cap | Lab G | Public | |
| 15 May 2026 | Tirzepatide | View | 40mg | 37.9mg | -5.3% | 99.70% | (no batch ID) | No Label / Silver Crimp / Pink Cap | Lab G | Public | |
| 13 May 2026 | GHK-Cu | View | 100mg | 51.9mg | -48.1% | 99.90% | January 4, 2026 | No Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 8 May 2026 | Retatrutide | View | 20mg | 10.6mg | -47.0% | 99.90% | January 4, 2026 | No Label / Silver Crimp / Yellow Cap | Lab E | Public | |
| 13 Mar 2026 | Retatrutide | View | 15mg | 16.1mg | +7.3% | 99.80% | 07/02/25 | White Label / Silver Crimp / Orange Cap | Lab G | Public | |
About Xingruida XDR Test Results From Finnrick
Xingruida XDR is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 6 products and 71 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Xingruida XDR Testing Activity & Score Summary
In the past 30 days, Finnrick has published 5 new test results for Xingruida XDR, and 7 in the past three months. The overall dataset includes 71 tested samples with an average score of 7.4/10 across all products.
Across 71 identity-tested samples, 100% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 97% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Tirzepatide (20 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 3.9 to 10.0 (average 7.0/10), suggesting significant batch-to-batch differences.
- GHK-Cu (9 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 4.7 to 10.0 (average 7.5/10), suggesting significant batch-to-batch differences.
- Retatrutide (25 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 3.6 to 10.0 (average 8.1/10), suggesting significant batch-to-batch differences.